{"entity":{"id":"kcnd3","kind":"target","name":"KCND3","aka":["potassium voltage-gated channel subfamily D member 3","A-type voltage-gated potassium channel KCND3","Kv4.3","KSHIVB","SCA22","SCA19"],"tldr":"KCND3 (A-type voltage-gated potassium channel KCND3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","summary":"Pore-forming (alpha) subunit of voltage-gated A-type potassium channels that mediates transmembrane potassium transport in excitable membranes, in brain and heart. In cardiomyocytes, may generate the transient outward potassium current I(To). In neurons, may conduct the transient subthreshold somatodendritic A-type potassium current (ISA).\n\nOpen Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes literature 0.17, animal model 0.48, genetic association 0.36, clinical 0.76).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:6239","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6239"},{"label":"UniProt Q9UK17","url":"https://www.uniprot.org/uniprotkb/Q9UK17/entry"},{"label":"NCBI Gene 3752","url":"https://www.ncbi.nlm.nih.gov/gene/3752"},{"label":"Ensembl ENSG00000171385","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171385"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.76. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"KCND3","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:6239","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6239","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9UK17","url":"https://www.uniprot.org/uniprotkb/Q9UK17/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000171385","url":"https://platform.opentargets.org/target/ENSG00000171385/associations","note":"association with cancer (MONDO_0004992) 0.54;  (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCND3: RNA tissue enhanced (brain 29 nTPM); no normal tissue stained high; highest cancer staining carcinoid (1 of 4 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas KCND3 tissue","url":"https://www.proteinatlas.org/ENSG00000171385-KCND3/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000171385 associations","url":"https://platform.opentargets.org/target/ENSG00000171385/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:6239","ensembl":"ENSG00000171385","uniprot":"Q9UK17","entrez":"3752","firstDescribed":1998,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Kong et al, Am. J. Physiol, 1998, \"Isolation and characterization of the human gene encoding Ito: further diversity by alternative mRNA splicing\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9843794/","biology":"Pore-forming (alpha) subunit of voltage-gated A-type potassium channels that mediates transmembrane potassium transport in excitable membranes, in brain and heart. In cardiomyocytes, may generate the transient outward potassium current I(To). In neurons, may conduct the transient subthreshold somatodendritic A-type potassium current (ISA). Kinetics properties are characterised by fast activation at subthreshold membrane potentials, rapid inactivation, and quick recovery from inactivation. Channel properties are modulated by interactions with regulatory subunits. Interaction with the regulatory subunits KCNIP1 or KCNIP2 modulates the channel gating kinetics namely channel activation and inactivation kinetics and rate of recovery from inactivation. Location: Cell membrane; Cell membrane, sarcolemma; Cell projection, dendrite (UniProt). Locus 1p13.2 (HGNC).","whereFound":[],"targetClass":"other","prevalence":[]},"route":"/targets/kcnd3/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}]}}